Premium
A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.
Author(s) -
Patsalos PN
Publication year - 1990
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1990.tb03682.x
Subject(s) - carbamazepine , pharmacokinetics , dosing , pharmacology , metabolite , medicine , active metabolite , anticonvulsant , epilepsy , psychiatry
Using an open substitution study design, conventional carbamazepine (Tegretol, CBZ‐C and a chewable carbamazepine formulation (Tegretol Chewtabs, CBZ‐CHEW) were compared in 12 patients with severe intractable epilepsy. During a dosing interval, no significant differences were observed with respect to trough or peak serum concentrations of CBZ and CBZ‐10,11‐epoxide (CBZ‐E), the active metabolite. The area under the serum CBZ concentration‐time curve for a dosing interval was (mean +/− s.e. mean) 146 +/− 10 mumols l‐1 h on CBZ‐ C and 143 +/− 9 mumols l‐1 h on CBZ‐CHEW. The two formulations, therefore, have a similar pharmacokinetic profile and could be used interchangeably in the management of patients with epilepsy.